Entecavir Tablet-Entaliv 0.5mg

Q1: What is Entecavir (Entaliv 0.5mg) used for?

Entecavir 0.5mg is a first-line antiviral for chronic hepatitis B in treatment-naive patients. In HIV/HBV co-infected patients, it provides HBV suppression as part of a comprehensive antiretroviral strategy.

Q2: How does Entecavir work against hepatitis B?

Entecavir is a guanosine nucleoside analogue that, after phosphorylation, inhibits all three steps of HBV replication: base priming, reverse transcription, and positive-strand DNA synthesis. It is one of the most potent HBV-specific antivirals available.

Q3: What is the dosing for Entecavir 0.5mg?

For treatment-naive HBV: 0.5mg once daily on empty stomach. For lamivudine-resistant or treatment-experienced HBV: 1mg once daily on empty stomach. Take at least 2 hours before or 2 hours after eating. Take at a consistent time each day.

Q4: Is Entecavir also active against HIV?

Yes, Entecavir has HIV activity, but using it as anti-HIV monotherapy is strongly contraindicated — it rapidly selects for M184V resistance that compromises Lamivudine and Emtricitabine efficacy. In HIV/HBV co-infected patients, Entecavir should only be used as part of a fully suppressive HIV regimen.

Q5: What is the risk of stopping Entecavir suddenly?

Stopping Entecavir without maintaining HBV suppression can cause severe hepatitis flare (ALT spike, hepatic decompensation, and rarely, liver failure). This is particularly dangerous in patients with cirrhosis. Never stop without specialist guidance and ensure alternative HBV therapy is continued.

Q6: What are the most common side effects?

Entecavir is generally well-tolerated. Common side effects include headache, fatigue, nausea, and dizziness. The most serious risk is lactic acidosis — a rare but potentially fatal complication of nucleoside analogues.

Q7: What serious side effects require emergency care?

Seek immediate care for: signs of lactic acidosis (unusual muscle pain, weakness, breathing difficulty, nausea — a rare but serious risk), severe liver enzyme elevation (indicating hepatitis flare or hepatotoxicity), or signs of liver decompensation in cirrhotic patients.

Q8: How does Entecavir compare to Tenofovir for HBV?

Both Entecavir and Tenofovir are first-line HBV treatments with similar potency. Tenofovir (TAF or TDF) is preferred in HIV/HBV co-infected patients because it addresses both viruses. Entecavir is preferred for HBV mono-infection without HIV.

Q9: What kidney monitoring is needed for Entecavir?

Regular monitoring of renal function (creatinine, eGFR) is recommended, especially if eGFR is below 50 ml/min. Dose adjustment is required for renal impairment — consult prescribing information for specific adjustments.

Q10: Can Entecavir be used during pregnancy?

Limited human pregnancy data exists. Tenofovir-based regimens are generally preferred in pregnant women with HBV. Entecavir should only be used during pregnancy when the benefit clearly outweighs the risk — discuss with your specialist.

Q11: How should Entecavir 0.5mg be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q12: Do I need a prescription for Entecavir?

Yes. Entecavir requires specialist prescribing (hepatologist or HIV specialist) with baseline HBV testing and regular liver function monitoring throughout treatment.